IBXXF (Imagion Biosystems) Days Payable: 0.00 (As of Dec. 2025)


What is Imagion Biosystems Days Payable?

Imagion Biosystems IBXXF Days Payable is 0.00 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 523559.69% on this metric.

Imagion Biosystems's average Accounts Payable for the six months ended in Dec. 2025 was $0.88 Mil. Imagion Biosystems's Cost of Goods Sold for the six months ended in Dec. 2025 was $0.00 Mil.

The historical rank and industry rank for Imagion Biosystems's Days Payable or its related term are showing as below:

IBXXF's Days Payable is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 65.09
* Ranked among companies with meaningful Days Payable only.

Imagion Biosystems's Days Payable stayed the same from Dec. 2024 (0.00) to Dec. 2025 (0.00).

Imagion Biosystems Days Payable Historical Data

* Premium members only.

The historical data trend for Imagion Biosystems's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagion Biosystems Days Payable Chart

Imagion Biosystems Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Imagion Biosystems Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IBXXF vs TMO, DHR, IDXX: Days Payable Comparison

For the Diagnostics & Research subindustry, Imagion Biosystems's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems Days Payable vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Days Payable distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's Days Payable falls into.


Imagion Biosystems Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Imagion Biosystems's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (1.313 + 0.794) / 2 ) / 0*365
=1.0535 / 0*365
=N/A

Imagion Biosystems's Days Payable for the quarter that ended in Dec. 2025 is calculated as:

Days Payable (Q: Dec. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Jun. 2025 ) + Accounts Payable (Q: Dec. 2025 )) / count ) / Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=( (0.975 + 0.794) / 2 ) / 0*365 / 2
=0.8845 / 0*365 / 2
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Imagion Biosystems (IBXXF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 191 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' Days Payable too high?
Imagion Biosystems' current Days Payable is 0.00. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 191 companies for Days Payable. This places Imagion Biosystems in the lower half of its industry. The industry median Days Payable is 65.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.09, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.08, compared to a current price of $0.03 — trading 99% below its estimated fair value. The current Days Payable is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagion Biosystems Business Description

Other Exchanges IBX:Australia
Address 385 Bourke Street, Suite 2, Level 11, Melbourne, VIC, AUS, 3000
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.